Candid's Strategy with $370M Investment in Bispecifics for Autoimmune Diseases
Candid's Ambitious Venture into Bispecifics
Candid, with a substantial investment of $370 million, is on a mission to validate the potential of bispecifics in treating autoimmune diseases. According to the CEO, the focus is on T cell engagers as the optimal choice in developing new treatments for inflammatory diseases. This strategy positions Candid as a pivotal player in the evolving landscape of autoimmune therapies.
Why T Cell Engagers?
The startup contends that T cell engagers might be more effective than traditional cell therapies due to their unique mechanism of action. By targeting the immune system more precisely, these treatments promise to enhance patient outcomes in various inflammatory conditions.
- Investment in Research and Development
- Potential for Groundbreaking Treatments
- Focus on Inflammatory Disease Areas
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.